Showing results (431-440 of 588) with videos related to
Sort By:
Pageof 59
BJUI Compass|April 27, 2022
Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and managementNithesh Ranasinha, Altan Omer, Yiannis Philippou, et al.Nature Communications|December 13, 2024
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostateXuanrong Chen, Michael A Augello, Deli Liu, et al.Nature Communications|June 8, 2021
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancerNicholas J Brady, Alyssa M Bagadion, Richa Singh, et al.Cancer Immunology Research|November 24, 2020
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1Rupal S Bhatt, Abdulla Berjis, Julie C Konge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.Journal of the National Cancer Institute|May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational ResearchToni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.Cell Metabolism|April 15, 2014
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cellsHan Xie, Jun-Ichi Hanai, Jian-Guo Ren, et al.Cancer Cell|December 17, 2013
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancerLianjie Li, Chuan Shen, Eijiro Nakamura, et al.Journal for Immunotherapy of Cancer|November 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinomaAbhishek Tripathi, Edwin Lin, Wanling Xie, et al.Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.Pageof 59